Imaging of Sarcopenia in Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index; 19 of the 107 sources its claims cite were checked for support.
Abstract
Sarcopenia is an age-related condition characterized by the loss of skeletal muscle mass, muscular strength, and muscle function. In older adults, type 2 diabetes mellitus (T2DM) constitutes a significant health burden. Skeletal muscle damage and deterioration have emerged as novel chronic complications in patients with diabetes, often linked to their increased longevity. Diabetic sarcopenia has been associated with increased rates of hospitalization, cardiovascular events, and mortality. Nevertheless, effectively managing metabolic disorders in patients with T2DM through appropriate therapeutic interventions could potentially mitigate the risk of sarcopenia. Utilizing imaging technologies holds substantial clinical significance in the early detection of skeletal muscle mass alterations associated with sarcopenia. Such detection is pivotal for arresting disease progression and preserving patients' quality of life. These imaging modalities offer reproducible and consistent patterns over time, as they all provide varying degrees of quantitative data. This review primarily delves into the application of dual-energy X-ray absorptiometry, computed tomography, magnetic resonance imaging, and ultrasound for both qualitative and quantitative assessments of muscle mass in patients with T2DM. It also juxtaposes the merits and limitations of these four techniques. By understanding the nuances of each method, clinicians can discern how best to apply them in diverse clinical scenarios.
Overview
CoChat Summary
TL;DR
This narrative review summarizes imaging modalities—DXA, CT, MRI, and ultrasound—for qualitative and quantitative assessment of muscle mass in patients with type 2 diabetes mellitus (T2DM) and sarcopenia. It compares their advantages and limitations and argues that imaging is important for early detection, monitoring, and guiding interventions in diabetic sarcopenia.
Key findings
- Sarcopenia is defined as progressive and generalized loss of skeletal muscle mass and strength; muscle strength declines by 20–40% during the seventh and eighth decades of life.
- DXA-based low muscle mass cutoffs are ALMI < 5.5 kg/m² in women and < 7.0 kg/m² in men per EWGSOP, while AWGS suggests ALMI < 5.7 kg/m² in women and < 7.0 kg/m² in men for Asian populations.
- CT commonly uses skeletal muscle index cutoffs of 39–41 cm²/m² for females and 52–55 cm²/m² for males, but there is no universally recognized CT-based standard for sarcopenia diagnosis.
- Ultrasound shear-wave elastography reported average gastrocnemius stiffness of 12.51 ± 2.56 kPa in the relaxed state and 81.74 ± 15.77 kPa in the contracted state; MRI is described as the gold standard for body composition but is limited by cost, complexity, and availability.
Methods
- Narrative review of imaging techniques for sarcopenia in T2DM, focusing on dual-energy X-ray absorptiometry (DXA), computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US), with additional discussion of bioelectrical impedance analysis (BIA).
- The paper synthesizes prior literature and guidelines, including EWGSOP and AWGS definitions and diagnostic approaches, rather than presenting primary data.
- It compares modalities by measures, simplicity, cost, validity, clinical application, and research application, and discusses associations between T2DM, muscle mass, exercise, and hypoglycemic medications.
Limitations
- Stated: CT lacks a universally recognized sarcopenia diagnostic standard because of population and criteria variations, and has high radiation dose, cost, and operational complexity; MRI has high costs, complexity, limited availability, and no standardized imaging protocols or biomarkers; US measurement of intermuscular adipose tissue lacks accuracy and consistency due to scanner subjectivity, probe angle, and pressure; BIA accuracy can be substantially affected by hydration status in older adults with T2DM.
- Stated: DXA may overestimate thigh muscle mass, especially in severely obese women, due to body thickness and hydration, and accuracy can be compromised if body length or arm spacing exceeds scanning dimensions.
- Evident from the text: this is a narrative review without a described systematic search strategy, meta-analysis, or primary cohort, so findings depend on the selected cited literature and do not provide new empirical estimates.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
15 Valid · 1 Not valid · 69 Not checked · 5 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among the strategies for preserving muscle quantity and quality, resistance exercise training is a reliable approach.1”
§ Imaging of Sarcopenia in Type 2 Diabetes Mellitus > Muscle Mass and Behavioral Interaction
What the sources say
- Partly supportedcites [1] Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48(1): 16– 31. 30312372 PMC6322506 sourceExperimental — accuracy not yet measured
The ‘Time course’ section says that interventions including exercise training seem to slow or reverse muscle weakening and progression toward impairment. It does not specifically identify resistance training as a reliable approach or establish that it preserves both muscle quantity and quality; the ‘Muscle quality measurement’ section discusses assessment rather than training effects. Page numbers are unavailable in our copy. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Through a comparison of data across different age groups and DXA-based sarcopenia assessments, other researchers47 identified significant differences in skeletal muscle mass between older and middle-aged patients with diabetes.”
§ Imaging of Sarcopenia in Type 2 Diabetes Mellitus > Imaging Techniques for Sarcopenia in Type 2 Diabetes Mellitus > Dual-Energy X-Ray Absorptiometry
What the sources say
- Supportedcites [47] Koo BK, Roh E, Yang YS, Moon MK. Difference between old and young adults in contribution of β-cell function and sarcopenia in developing diabetes mellitus. J Diabetes Invest. 2016; 7(2): 233– 240. PMC4773679 27042276 source
The Discussion states that elderly-onset diabetic patients had significantly lower skeletal muscle mass than middle-age-onset patients. The Methods describe whole-body DXA measurement of muscle mass and DXA-based assessment of sarcopenia, matching the cited comparison. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The role of nutritional intervention in preventing and treating sarcopenia is less straightforward; nevertheless, some data suggest that adopting healthier dietary patterns, including adequate amounts of protein, vitamin D, antioxidants, and long-chain polyunsaturated fatty acids, could confer benefits.25–27”
§ Imaging of Sarcopenia in Type 2 Diabetes Mellitus > Muscle Mass and Behavioral Interaction
What the sources say
- Supportedcites [25] Robinson SM, Reginster JY, Rizzoli R, et al. Does nutrition play a role in the prevention and management of sarcopenia? Clin Nutr. 2018; 37(4): 1121– 1132. 28927897 PMC5796643 source
The Foods and dietary patterns section says healthier diets tend to provide more protein, vitamin D, antioxidants, and long-chain polyunsaturated fatty acids. It also says observational evidence suggests whole-diet approaches have potential to prevent or treat age-related losses in muscle mass and strength. This matches the citing sentence’s cautious wording; page numbers were not available in our copy. (LLM, conf=0.92)
- Supportedcites [26] Bloom I, Shand C, Cooper C, Robinson S, Baird J. Diet quality and sarcopenia in older adults: a systematic review. Nutrients. 2018; 10: 3. PMC5872726 29510572 source
The Introduction says improving diet and nutrition may help prevent and treat sarcopenia. The Discussion identifies protein, vitamin D, antioxidants and long-chain polyunsaturated fatty acids as nutrients associated with healthier diets and muscle function. The Conclusions frame whole-diet approaches as promising but in need of intervention studies, consistent with the claim’s cautious wording. (LLM, conf=0.90)
- Not checked yetcites [27] van Dronkelaar C, van Velzen A, Abdelrazek M, van der Steen A, Weijs PJM, Tieland M. Minerals and sarcopenia; the role of calcium, iron, magnesium, phosphorus, potassium, selenium, sodium, and zinc on muscle mass, muscle strength, and physical performance in older adults: a systematic review. J Am Med Directors Assoc. 2018; 19(1): 6– 11.e3. 28711425 source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This technique quantifies IMCL and extracellular (EMCL) lipids, minimizing potential errors related to manual EMCL adipose tissue removal.74”
§ Imaging of Sarcopenia in Type 2 Diabetes Mellitus > Imaging Techniques for Sarcopenia in Type 2 Diabetes Mellitus > Magnetic Resonance Imaging
What the sources say
- Supportedcites [74] Hwang JH, Choi CS. Use of in vivo magnetic resonance spectroscopy for studying metabolic diseases. Exp Mol Med. 2015; 47(2): e139. 25656949 PMC4346484 source
The 1H MRS section ('1H MRS for intramyocellular lipids') states that 1H MRS allows IMCL and EMCL lipid quantitation without manual cleaning of EMCL adipose tissue, and that the modality 'removes potential quantification errors that originated from incomplete manual EMCL cleaning'. This matches the citing sentence's attribution both in content and scope (muscular IMCL/EMCL, error minimization relative to manual removal). (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“ATP levels and other phosphorus metabolites are linked to metabolic changes in insulin-resistant T2DM.76”
§ Imaging of Sarcopenia in Type 2 Diabetes Mellitus > Imaging Techniques for Sarcopenia in Type 2 Diabetes Mellitus > Magnetic Resonance Imaging
What the sources say
- Supportedcites [76] Szendroedi J, Chmelik M, Schmid AI, et al. Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology. 2009; 50(4): 1079– 1086. 19637187 source
The Hepatic Phosphorus Metabolites section reports lower hepatic γATP and inorganic phosphate (Pi) in people with T2DM and negative relationships between both metabolites and hepatic insulin resistance, HbA1c, BMI, and liver fat. These findings support the claimed link between ATP, another phosphorus metabolite, and metabolic changes in insulin-resistant T2DM. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
38 more claims · 4 with their cited sources checked
Create a free account to see all 90 claims and to verify the 88 references still open.
- Probably not a substantial claim. 25
- It may state two separate claims as one. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the other hand, SMI may be a better predictor of sarcopenia in type 2 diabetes than LBM, and should be taken into account as a crucial outcome measure in future clinical investigations [66].”
From Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis (2025) · cites this paper as [66]
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 1×
“The recent guidelines from EWGSOP have made slight modifications to previous diagnostic cutoff values, proposing an ALMI 5.5 kg/m 2 in women and ALMI 7.0 kg/m 2 in men be used as criteria for defining low muscle mass (1).”
MethodInfluentialAsian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Chen, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Chou, M.-Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.012 · Cited by 7,070 · cited 1×
“Additionally, the AWGS suggests an ALMI 5.7 kg/m 2 in women and ALMI 7.0 kg/m 2 in men, taking into account the anthropometric characteristics of the Asian population (2).”
BackgroundInfluentialMechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 1×
“50 In cases of obese patients with sarcopenia and T2DM, DXA measurements might overstate muscle mass, potentially leading to treatment delays.”
BackgroundSarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 1×
“15 Central to the diagnosis of sarcopenia is the measurement of muscle mass. Clinical practice and research employ diverse qualitative and quantitative methodologies to ascertain muscle mass. Imaging modalities, including dual-energy X-ray absorptiometry (DXA), computed tomography (CT), magnetic…”
MethodSarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399
Mitochondrial dysfunction in the elderly: possible role in insulin resistance
Petersen, K. F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D. L., DiPietro, L., Cline, G. W., & Shulman, G. I. (2003) · Science · doi:10.1126/science.1082889 · Cited by 2,107 · cited 1×
“77,78 Thus, 31 P MRS assessment of enzyme activity and mitochondrial function plays a crucial role in studying metabolic shifts, aging, and diseases.”
BackgroundCruz-Jentoft, A. J., Landi, F., Schneider, S. M., Zuniga, C., Arai, H., Boirie, Y., Chen, L.-K., Fielding, R. A., Martin, F. C., Michel, J.-P., et al. (2014) · Age and Ageing · doi:10.1093/ageing/afu115 · Cited by 1,963
DeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., & Felber, J. P. (1981) · Diabetes · doi:10.2337/diab.30.12.1000 · Cited by 1,770 · cited 1×
“17 As individuals age, there is a gradual decline in mitochondrial function in human skeletal muscle along with a decrease in muscle mass, strength, and overall muscle function.”
BackgroundInvited Review: Aging and sarcopenia
Doherty, T. J. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00347.2003 · Cited by 1,764
Shen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692 · cited 1×
“Although Steven Heymsfield utilized CT for analyzing body composition in the 1980s, 51 Shen et al 52 did not present a method for calculating whole-body skeletal muscle and adipose tissue from a single abdomen CT cross-sectional scan until 2004.”
Method
Cited by
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101681 · Cited by 30
GLP-1 and Its Role in Glycogen Production: A Narrative Review
Lotosky, J., Jean, X., Altankhuyag, A., Khan, S. R., Bernotas, A., Sharafshah, A., Blum, K., Posner, A. R., & Thanos, P. K. (2025) · Biomedicines · doi:10.3390/biomedicines13071610 · Cited by 17
“Along with the debilitation of skeletal muscle, as individuals with T2DM age, there is a gradual decline in mitochondrial function in human skeletal muscle along with a decrease in muscle mass, strength, and overall muscle function [31].”
Wang, Y., Lan, B., Zhang, S., Mu, Y., Mi, J., Yu, J., Zhan, Q., Luo, B., Lin, F., Teng, J., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01877-4 · Cited by 8
“On the other hand, SMI may be a better predictor of sarcopenia in type 2 diabetes than LBM, and should be taken into account as a crucial outcome measure in future clinical investigations [66].”
Bibliometric mapping of diabetes mellitus and sarcopenia research: hotspots and emerging trends
Wang, M., Zhou, Q., Guo, X., Cui, X., Tang, Z., Ou, T., Zhao, X., Chen, L., Xu, P., Dai, X., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1586308 · Cited by 8
Toro, J. J. O. (2025) · Endocrines · doi:10.3390/endocrines6030047 · Cited by 7
“While most modalities can evaluate muscle quality in research settings, only DXA currently offers routine clinical measures [11].”
InfluentialSarcopenia in type 2 diabetes mellitus: an imaging review
He, L., Luo, G., Jiang, H., Zhang, L., Li, Y., Gu, W., Zeng, Q., Zhu, J., Liu, J., Lei, H., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1637499 · Cited by 6
“Thus, it is essential to consider these factors when interpreting DXA results to ensure the reliability of body composition assessments and timely medical interventions (102).”
Ma, X., Rao, Z., Jin, Z., Lu, Y., Sun, Z., & Zheng, L. (2025) · Biomolecules · doi:10.3390/biom16010003 · Cited by 8
“Diabetes is a well-established risk factor for muscle atrophy [3], with diabetic individuals exhibiting a more pronounced decline in skeletal muscle mass and strength compared to non-diabetic counterparts.”
Sex-specific associations between type 2 diabetes and muscle health in middle-aged adults
Wang, Y., Gao, S., Xu, Q., & Zhu, Z. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01963-7 · Cited by 2
“Evidence indicates an amplified prevalence of sarcopenia among T2DM patients, with accelerated decline in skeletal muscle function compared to healthy counterparts [9, 10].”
Association between higher eating frequency and lower odds of low muscle mass in Koreans
Chun, M., & Lee, S. R. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1663242 · Cited by 1
Correlation Between Various Insulin Resistance Indices and Sarcopenia: Evidence from CHARLSPreprint
Xu, K., Liu, R., Chen, B., & Jing, L. (2026) · Research Square · doi:10.21203/rs.3.rs-8404542/v1
Grippa, P. C., Quesada, K. R., Barboza, G. D. O., Marvulle, M. E. G., Candido, D., Machado, N. M., Laurindo, L. F., Araújo, A. C., de Lima, E. P., Guiguer, É. L., et al. (2026) · Medicina · doi:10.3390/medicina62010182
“The CSA of skeletal muscles (SMA, cm 2 ) at the level of the third lumbar vertebra (L3), normalized by height squared (m 2 ), can be used to calculate the SMI (cm 2 /m 2 ), which is linearly related to whole-body muscle mass [43–46].”
Metadata
- Authors
- Wang, D., Zhang, G., Yu, Y., & Zhang, Z.
- Affiliations
- First Hospital of China Medical University (CN)
- Corresponding author
- Wang, Dingyue
- Zhang, Gaosen
- Yu, Yana
- Zhang, Zhen
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2024-01
- Volume
- Volume 19
- Pages
- 141-151
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- PMC
- PMC10826713
- OpenAlex
- W4391271840
- Semantic Scholar
- 26d59dbd595de403946d6a006a14a79c752c803f
- Cited by
- 11
- References
- 103
- Citations by year
- 2026: 4 · 2025: 7
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Interventions in Aging (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- sarcopenia, type 2 diabetes, skeletal muscle mass, muscle imaging, dual-energy X-ray absorptiometry, computed tomography, magnetic resonance imaging, ultrasound, diabetes complications, older adults
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Humans, Quality of Life, Muscle, Skeletal, Muscle Strength, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.